Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 101–200 of 4,628
Behr, J., Kreuter, M., Hoeper, M. M., Wirtz, H., Klotsche, J., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00217614 · Cited by 247
Käsmann, L., Dietrich, A., Staab-Weijnitz, C. A., Manapov, F., Behr, J., Rimner, A., Jeremic, B., Senan, S., De Ruysscher, D., Lauber, K., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01654-9 · Cited by 245
Crestani, B., Huggins, J. T., Kaye, M., Costabel, U., Glaspole, I., Ogura, T., Song, J. W., Stansen, W., Quaresma, M., Stowasser, S., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30339-4 · Cited by 247
Self-citationSalisbury, M. L., Myers, J. L., Belloli, E. A., Kazerooni, E. A., Martinez, F. J., & Flaherty, K. R. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1675pp · Cited by 243
Self-citationNovel mechanisms for the antifibrotic action of nintedanib
Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., Antony, V. B., Zhang, J., Zmijewski, J., & Thannickal, V. J. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0445oc · Cited by 238
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201737 · Cited by 236
Self-citationNintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Kolb, M., Richeldi, L., Behr, J., Maher, T. M., Tang, W., Stowasser, S., Hallmann, C., & du Bois, R. M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208710 · Cited by 235
Self-citationVisca, D., Mori, L., Tsipouri, V., Fleming, S., Firouzi, A., Bonini, M., Pavitt, M. J., Alfieri, V., Canu, S., Bonifazi, M., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30289-3 · Cited by 235
The Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
Ahluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01592-2016 · Cited by 233
Maher, T. M., van der Aar, E. M., Van de Steen, O., Allamassey, L., Desrivot, J., Dupont, S., Fagard, L., Ford, P., Fieuw, A., & Wuyts, W. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30181-4 · Cited by 231
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
Strongman, H., Kausar, I., & Maher, T. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0693-1 · Cited by 233
The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis
Murtha, L. A., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Knight, D. A., & Boyle, A. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00777 · Cited by 229
Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312346 · Cited by 227
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., Wijsenbeek, M. S., Vasakova, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2018) · JAMA · doi:10.1001/jama.2018.6129 · Cited by 227
Self-citationCottin, V., Selman, M., Inoue, Y., Wong, A. W., Corte, T. J., Flaherty, K. R., Han, M. K., Jacob, J., Johannson, K. A., Kitaichi, M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202206-1041st · Cited by 226
Self-citationThe mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Petnak, T., Lertjitbanjong, P., Thongprayoon, C., & Moua, T. (2021) · Chest · doi:10.1016/j.chest.2021.06.049 · Cited by 220
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
Hirani, N., MacKinnon, A. C., Nicol, L., Ford, P., Schambye, H., Pedersen, A., Nilsson, U. J., Leffler, H., Sethi, T., Tantawi, S., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02559-2020 · Cited by 220
COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts
John, A. E., Joseph, C., Jenkins, G., & Tatler, A. L. (2021) · Immunological Reviews · doi:10.1111/imr.12977 · Cited by 219
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis
Kreuter, M., Wuyts, W., Renzoni, E., Koschel, D., Maher, T. M., Kolb, M., Weycker, D., Spagnolo, P., Kirchgaessler, K.-U., Herth, F. J. F., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00067-9 · Cited by 218
Self-citationProgressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Nasser, M., Larrieu, S., Si-Mohamed, S., Ahmad, K., Boussel, L., Brevet, M., Chalabreysse, L., Fabre, C., Marque, S., Revel, D., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02718-2020 · Cited by 217
Self-citationHighland, K. B., Distler, O., Kuwana, M., Allanore, Y., Assassi, S., Azuma, A., Bourdin, A., Denton, C. P., Distler, J. H. W., Hoffmann-Vold, A. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30330-1 · Cited by 217
Self-citationSolomon, J. J., Danoff, S. K., Woodhead, F. A., Hurwitz, S., Maurer, R., Glaspole, I., Dellaripa, P. F., Gooptu, B., Vassallo, R., Cox, P. G., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00260-0 · Cited by 216
Self-citationSafety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00198013 · Cited by 215
Self-citationMesothelial cells in tissue repair and fibrosis
Mutsaers, S. E., Birnie, K., Lansley, S., Herrick, S. E., Lim, C.-B., & Prêle, C. M. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00113 · Cited by 210
Palmer, S. M., Snyder, L., Todd, J. L., Soule, B., Christian, R., Anstrom, K., Luo, Y., Gagnon, R., & Rosen, G. (2018) · Chest · doi:10.1016/j.chest.2018.08.1058 · Cited by 202
“Any AE 35 (75) 36 (75) 45 (94) AEs (incidence $ 10% in any group) Cough 6 (13) 3 (6) 11 (23) Headache 4 (9) 1 (2) 8 (17) Fatigue 2 (4) 4 (8) 7 (15) Arthralgia 0 (0) 3 (6) 5 (10) Blood ALP increased 0 (0) 1 (2) 5 (10) Nasopharyngitis 3 (6) 5 (10) 4 (8) Overdose 6 (13) 1 (2) 4 (8) Bronchitis 3 (6) 6 (13) 1 (2) SAEs 12 (…”
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Wind, S., Schmid, U., Freiwald, M., Marzin, K., Lotz, R., Ebner, T., Stopfer, P., & Dallinger, C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00766-0 · Cited by 212
CT of Post-Acute Lung Complications of COVID-19
Solomon, J. J., Heyman, B., Ko, J. P., Condos, R., & Lynch, D. A. (2021) · Radiology · doi:10.1148/radiol.2021211396 · Cited by 212
Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing
Peyser, R., MacDonnell, S., Gao, Y., Cheng, L., Kim, Y., Kaplan, T., Ruan, Q., Wei, Y., Ni, M., Adler, C., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0313oc · Cited by 210
Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0621-y · Cited by 210
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey
Cosgrove, G. P., Bianchi, P., Danese, S., & Lederer, D. J. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0560-x · Cited by 208
Lung cancer and interstitial lung disease: a literature review
Naccache, J.-M., Gibiot, Q., Monnet, I., Antoine, M., Wislez, M., Chouaid, C., & Cadranel, J. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.75 · Cited by 208
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Self-citationLancaster, L., Crestani, B., Hernandez, P., Inoue, Y., Wachtlin, D., Loaiza, L., Quaresma, M., Stowasser, S., & Richeldi, L. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000397 · Cited by 209
“Event rates of MACE and MI in the pooled nintedanib population were low and consistent with those observed in nintedanib-treated patients in the INPULSIS trials.(9) In postmarketing surveillance data collected in the USA in the year following the launch of nintedanib as a treatment for IPF, the incidence rates of MACE…”
MethodResultSelf-citationFinnerty, J. P., Ponnuswamy, A., Dutta, P., Abdelaziz, A., & Kamil, H. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01783-1 · Cited by 209
The importance of interventional timing in the bleomycin model of pulmonary fibrosis
Kolb, P., Upagupta, C., Vierhout, M., Ayaub, E., Bellaye, P. S., Gauldie, J., Shimbori, C., Inman, M., Ask, K., & Kolb, M. R. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.01105-2019 · Cited by 208
Self-citationAcute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm
Ryerson, C. J., Cottin, V., Brown, K. K., & Collard, H. R. (2015) · European Respiratory Journal · doi:10.1183/13993003.00419-2015 · Cited by 205
Self-citationMechanisms of Alveolar Epithelial Injury, Repair, and Fibrosis
Chambers, R. C., & Mercer, P. F. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201410-448mg · Cited by 202
Predicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis
Jacob, J., Bartholmai, B. J., Rajagopalan, S., van Moorsel, C. H. M., van Es, H. W., van Beek, F. T., Struik, M. H. L., Kokosi, M., Egashira, R., Brun, A. L., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2174oc · Cited by 198
Computed Tomography: Revolutionizing the Practice of Medicine for 40 Years
Rubin, G. D. (2014) · Radiology · doi:10.1148/radiol.14141356 · Cited by 197
Dressen, A., Abbas, A. R., Cabanski, C., Reeder, J., Ramalingam, T. R., Neighbors, M., Bhangale, T. R., Brauer, M. J., Hunkapiller, J., Reeder, J., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30135-8 · Cited by 196
Self-citationHuang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207109 · Cited by 196
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30007-9 · Cited by 196
Self-citationBehr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Herzog, E. L., Mathur, A., Tager, A. M., Feghali‐Bostwick, C., Schneider, F., & Varga, J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38702 · Cited by 193
BTS Clinical Statement on pulmonary sarcoidosis
Thillai, M., Atkins, C. P., Crawshaw, A., Hart, S. P., Ho, L.-P., Kouranos, V., Patterson, K. C., Screaton, N. J., Whight, J., & Wells, A. U. (2021) · Thorax · doi:10.1136/thoraxjnl-2019-214348 · Cited by 194
The genetic basis of idiopathic pulmonary fibrosis
Kropski, J. A., Blackwell, T. S., & Loyd, J. E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00163814 · Cited by 193
Idiopathic Pulmonary Fibrosis – Diagnosis and Treatment
Bendstrup, E. (2014) · General Medicine: Open Access · doi:10.4172/2327-5146.1000161 · Cited by 192
Natural history of idiopathic pulmonary fibrosis
Kim, H. J., Perlman, D., & Tomic, R. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.02.002 · Cited by 191
Mitochondrial quality control in pulmonary fibrosis
Larson-Casey, J. L., He, C., & Carter, A. B. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101426 · Cited by 189
Hansell, D. M., Goldin, J. G., King, T. E., Lynch, D. A., Richeldi, L., & Wells, A. U. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00096-x · Cited by 189
Self-citationTreatment of primary Sjögren syndrome
Saraux, A., Pers, J.-O., & Devauchelle-Pensec, V. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.100 · Cited by 188
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Kreuter, M., Lee, J. S., Tzouvelekis, A., Oldham, J. M., Molyneaux, P. L., Weycker, D., Atwood, M., Kirchgaessler, K.-U., & Maher, T. M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202003-0669oc · Cited by 187
Drug Treatment of Idiopathic Pulmonary Fibrosis
Canestaro, W. J., Forrester, S. H., Raghu, G., Ho, L., & Devine, B. E. (2016) · Chest · doi:10.1016/j.chest.2015.11.013 · Cited by 186
Self-citationRomagnoli, M., Colby, T. V., Berthet, J.-P., Gamez, A. S., Mallet, J.-P., Serre, I., Cancellieri, A., Cavazza, A., Solovei, L., Dell’Amore, A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1947oc · Cited by 187
Buyse, G. M., Voit, T., Schara, U., Straathof, C. S. M., D'Angelo, M. G., Bernert, G., Cuisset, J.-M., Finkel, R. S., Goemans, N., McDonald, C. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60025-3 · Cited by 185
Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities
King, C. S., & Nathan, S. D. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30222-3 · Cited by 186
Progression of fibrosing interstitial lung disease
Wong, A. W., Ryerson, C. J., & Guler, S. A. (2020) · Respiratory Research · doi:10.1186/s12931-020-1296-3 · Cited by 185
Kadota, T., Fujita, Y., Araya, J., Watanabe, N., Fujimoto, S., Kawamoto, H., Minagawa, S., Hara, H., Ohtsuka, T., Yamamoto, Y., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12124 · Cited by 187
“…treatment modalities, such as pir-fenidone (PFD) and nintedanib, significantly reduce the decline of forced vital capacity, these drugs neither promote recovery nor prevent the progression of functional decline and the structural distortion seen in IPF (King et al., 2014; Richeldi et al., 2014).”
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 184
Raghu, G., & Selman, M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2044ed · Cited by 185
Self-citationFlaherty, K. R., Brown, K. K., Wells, A. U., Clerisme-Beaty, E., Collard, H. R., Cottin, V., Devaraj, A., Inoue, Y., Le Maulf, F., Richeldi, L., et al. (2017) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000212 · Cited by 184
Self-citationA Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly
Knüppel, L., Ishikawa, Y., Aichler, M., Heinzelmann, K., Hatz, R., Behr, J., Walch, A., Bächinger, H. P., Eickelberg, O., & Staab-Weijnitz, C. A. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0217oc · Cited by 183
Huang, J., Maier, C., Zhang, Y., Soare, A., Dees, C., Beyer, C., Harre, U., Chen, C.-W., Distler, O., Schett, G., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210823 · Cited by 182
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Lawrence, J., & Nho, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183
Therapeutic Effects of Coumarins with Different Substitution Patterns
Flores-Morales, V., Villasana-Ruíz, A. P., Garza-Veloz, I., González-Delgado, S., & Martinez-Fierro, M. L. (2023) · Molecules · doi:10.3390/molecules28052413 · Cited by 183
“So far, o ly pirf nidone and ninted nib have been approv by the United States Food and Drug Administration (FDA) for the treatment of IPF [57,58].”
BackgroundInfluentialAcute exacerbations of progressive-fibrosing interstitial lung diseases
Kolb, M., Bondue, B., Pesci, A., Miyazaki, Y., Song, J. W., Bhatt, N. Y., Huggins, J. T., Oldham, J. M., Padilla, M. L., Roman, J., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0071-2018 · Cited by 182
Self-citationCurrent and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
Xu, Z., Ren, F., Wang, P., Cao, J., Tan, C., Ma, D., Zhao, L., Dai, J., Ding, Y., Fang, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03743-2 · Cited by 180
Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0402oc · Cited by 180
Self-citationNathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Glasscock, K. F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207011 · Cited by 180
Self-citationDaily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis
Grimminger, F., Günther, A., & Vancheri, C. (2015) · European Respiratory Journal · doi:10.1183/09031936.00149614 · Cited by 178
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review
Kinoshita, T., & Goto, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061461 · Cited by 176
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Corte, T., Bonella, F., Crestani, B., Demedts, M. G., Richeldi, L., Coeck, C., Pelling, K., Quaresma, M., & Lasky, J. A. (2015) · Respiratory Research · doi:10.1186/s12931-015-0276-5 · Cited by 175
Self-citationDésogère, P., Tapias, L. F., Hariri, L. P., Rotile, N. J., Rietz, T. A., Probst, C. K., Blasi, F., Day, H., Mino-Kenudson, M., Weinreb, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf4696 · Cited by 175
Winterbottom, C. J., Shah, R. J., Patterson, K. C., Kreider, M. E., Panettieri, R. A., Rivera-Lebron, B., Miller, W. T., Litzky, L. A., Penning, T. M., Heinlen, K., et al. (2018) · Chest · doi:10.1016/j.chest.2017.07.034 · Cited by 173
Selvarajah, B., Azuelos, I., Platé, M., Guillotin, D., Forty, E. J., Contento, G., Woodcock, H. V., Redding, M., Taylor, A., Brunori, G., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav3048 · Cited by 172
“Although the approval of pirfenidone and the small molecule tyrosine kinase inhibitor, nintedanib, for the treatment of IPF represented a watershed moment for the development of anti-fibrotic therapeutics, these agents slow but do not halt disease progression (4, 5).”
BackgroundIdiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history
Sgalla, G., Biffi, A., & Richeldi, L. (2016) · Respirology · doi:10.1111/resp.12683 · Cited by 173
Self-citationLung cancer in patients with idiopathic pulmonary fibrosis
Karampitsakos, T., Tzilas, V., Tringidou, R., Steiropoulos, P., Aidinis, V., Papiris, S. A., Bouros, D., & Tzouvelekis, A. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.03.016 · Cited by 171
Transcriptional regulatory model of fibrosis progression in the human lung
McDonough, J. E., Ahangari, F., Li, Q., Jain, S., Verleden, S. E., Herazo-Maya, J., Vukmirovic, M., DeIuliis, G., Tzouvelekis, A., Tanabe, N., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131597 · Cited by 174
“by convincing evidence that immunosuppressive therapies have a detrimental effect on the patient and that recently developed antifibrotic drugs are effective in slowing the progression of the disease (6, 7).”
BackgroundPulmonary Rehabilitation in Interstitial Lung Disease
Koltharkar, M. (2021) · International Journal of Cardiovascular Research · Cited by 173
Acute Exacerbation in Interstitial Lung Disease
Leuschner, G., & Behr, J. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00176 · Cited by 171
Quantitative CT Analysis of Diffuse Lung Disease
Chen, A., Karwoski, R. A., Gierada, D. S., Bartholmai, B. J., & Koo, C. W. (2020) · RadioGraphics · doi:10.1148/rg.2020190099 · Cited by 168
Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production
Nigdelioglu, R., Hamanaka, R. B., Meliton, A. Y., O'Leary, E., Witt, L. J., Cho, T., Sun, K., Bonham, C., Wu, D., Woods, P. S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.756247 · Cited by 169
Inui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
Rogliani, P., Calzetta, L., Cavalli, F., Matera, M. G., & Cazzola, M. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.07.009 · Cited by 168
Hughes, G., Toellner, H., Morris, H., Leonard, C., & Chaudhuri, N. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090078 · Cited by 166
Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis
Tjin, G., White, E. S., Faiz, A., Sicard, D., Tschumperlin, D. J., Mahar, A., Kable, E. P. W., & Burgess, J. K. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.030114 · Cited by 163
Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis
Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Burgess, J. K., Mutsaers, S. E., Prele, C. M., Schuliga, M., Grainge, C. L., & Knight, D. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2018 · Cited by 163
Vannan, A., Lyu, R., Williams, A. L., Negretti, N. M., Mee, E. D., Hirsh, J., Hirsh, S., Hadad, N., Nichols, D. S., Calvi, C. L., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02080-x · Cited by 161
Chen, H., Senan, S., Nossent, E. J., Boldt, R. G., Warner, A., Palma, D. A., & Louie, A. V. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.03.010 · Cited by 162
Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis
Wang, J. M., Robertson, S. H., Wang, Z., He, M., Virgincar, R. S., Schrank, G. M., Smigla, R. M., O’Riordan, T. G., Sundy, J., Ebner, L., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2017-210070 · Cited by 162
Chung, J. H., Cox, C. W., Montner, S. M., Adegunsoye, A., Oldham, J. M., Husain, A. N., Vij, R., Noth, I., Lynch, D. A., & Strek, M. E. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.17.18384 · Cited by 163
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01487-0 · Cited by 161
Pulmonary fibrosis secondary to COVID-19: a narrative review
Tanni, S. E., Fabro, A. T., de Albuquerque, A., Ferreira, E. V. M., Verrastro, C. G. Y., Sawamura, M. V. Y., Ribeiro, S. M., & Baldi, B. G. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1916472 · Cited by 161
Sisson, T. H., Ajayi, I. O., Subbotina, N., Dodi, A. E., Rodansky, E. S., Chibucos, L. N., Kim, K. K., Keshamouni, V. G., White, E. S., Zhou, Y., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.12.005 · Cited by 158
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.